| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/14/2022 | -1.96% | Canaccord Genuity | $12.5 → $2.5 | Downgrades | Buy → Hold |
| 07/07/2022 | — | Alliance Global Partners | Downgrades | Buy → Neutral | |
| 07/07/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 02/18/2022 | -72.55% | Alliance Global Partners | → $0.7 | Upgrades | Neutral → Buy |
| 01/27/2021 | -5.88% | Alliance Global Partners | $2.6 → $2.4 | Downgrades | Buy → Neutral |
| 01/27/2021 | 17.65% | SVB Leerink | $4 → $3 | Maintains | Outperform |
| 11/05/2020 | 37.25% | Canaccord Genuity | $4 → $3.5 | Maintains | Buy |
| 11/05/2020 | 56.86% | SVB Leerink | $3 → $4 | Maintains | Outperform |
| 10/08/2020 | -1.96% | BTIG | → $2.5 | Initiates Coverage On | → Buy |
| 08/12/2020 | 17.65% | SVB Leerink | $2 → $3 | Maintains | Outperform |
| 07/16/2020 | 56.86% | Canaccord Genuity | $3 → $4 | Maintains | Buy |
| 05/06/2020 | -21.57% | SVB Leerink | $5 → $2 | Reiterates | → Outperform |
| 11/26/2019 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral | |
| 09/12/2019 | 96.08% | SVB Leerink | $3 → $5 | Reiterates | → Outperform |
| 09/12/2019 | — | Janney Montgomery Scott | Upgrades | Neutral → Buy | |
| 08/01/2019 | -84.31% | Alliance Global Partners | $5 → $0.4 | Downgrades | Buy → Neutral |
| 07/31/2019 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 07/31/2019 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral | |
| 05/16/2019 | 96.08% | Alliance Global Partners | → $5 | Initiates Coverage On | → Buy |
| 06/01/2018 | — | Leerink Swann | Upgrades | Market Perform → Outperform | |
| 05/09/2018 | — | Janney Montgomery Scott | Upgrades | Neutral → Buy | |
| 03/29/2018 | 233.33% | HC Wainwright & Co. | $8 → $8.5 | Maintains | Buy |
| 01/29/2018 | 103.92% | Goldman Sachs | → $5.2 | Initiates Coverage On | → Neutral |
| 10/18/2017 | 213.73% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
T2 Biosystems Questions & Answers
The latest price target for T2 Biosystems (NASDAQ: TTOO) was reported by Canaccord Genuity on October 14, 2022. The analyst firm set a price target for $2.50 expecting TTOO to fall to within 12 months (a possible -1.96% downside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for T2 Biosystems (NASDAQ: TTOO) was provided by Canaccord Genuity, and T2 Biosystems downgraded their hold rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of T2 Biosystems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for T2 Biosystems was filed on October 14, 2022 so you should expect the next rating to be made available sometime around October 14, 2023.
While ratings are subjective and will change, the latest T2 Biosystems (TTOO) rating was a downgraded with a price target of $12.50 to $2.50. The current price T2 Biosystems (TTOO) is trading at is $2.55, which is out of the analyst's predicted range.
